-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Kraig Biocraft Laboratories Enters Biomedical Field with First Sample Shipments of Fibers and Fabrics for Tissue Engineering
Kraig Biocraft Laboratories Enters Biomedical Field with First Sample Shipments of Fibers and Fabrics for Tissue Engineering
ANN ARBOR, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces the first sample shipment of its recombinant spider silk fibers and fabrics for use and evaluation into a range of biomedical applications. This shipment was made in response to the significant increase in the requests for its propriety spider silk technology, over the last two quarters, for tissue engineering applications.
Aided by its unique blend of mechanical and chemical properties, spider silk has long been recognized as an ideal natural biomaterial. As a lightweight, biocompatible, and biodegradable material, spider silk applications have been tested in numerous morphologies, including; fibers, films, hydrogels, non-woven fabrics, foams, etc. While the first known cases of sutures made from spider silk date back to the 18th century, limitations in the production and costs of spider silk have prevented its broad adoption.
Kraig Labs' revolutionary approach, creating recombinant spider silk technology utilizing genetically enhanced silkworms, unlocks the door for large-scale adoption of spider silk for biomedical applications. This system merges the performance of spider silk with the well-established, large-scale supply chain for mundane silk.
With the growth of its production operations in Vietnam over the last two quarters, the Company is now positioned to allot a portion of its spider silk production to address the medical community's needs. This week's shipments are just the first in what the Company hopes will be a significant mid to long-term market growth opportunity for Kraig Labs and its foray into the growing field of bioengineering.
"Over the last month, we have seen a significant increase in the demand from the medical field for our spider silk fibers and fabrics," said COO, Jon Rice. "With the great work our team in Vietnam has done, increasing monthly silk production, we are now positioned to begin supplying R&D samples for this new and exciting end market. As these applications often require FDA approval, we believe the biomedical space has the potential to play an important role in the Company's long-term growth. Over the coming months, we will be closely monitoring the results of these first tests and assessing additional opportunities for the spider silk gels and films that we have already developed into the broad field of biomaterials."
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to .
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
ANN ARBOR, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces the first sample shipment of its recombinant spider silk fibers and fabrics for use and evaluation into a range of biomedical applications. This shipment was made in response to the significant increase in the requests for its propriety spider silk technology, over the last two quarters, for tissue engineering applications.
密歇根州安娜堡,2022年5月17日(Global Newswire)--专注于蜘蛛丝的开发和商业化的生物技术公司克莱格生物工艺实验室公司(场外交易市场代码:KBLB)(以下简称“公司”或“克莱格实验室”)宣布了其重组蜘蛛丝纤维和织物的第一批样品发货,用于在一系列生物医学应用中使用和评估。这批货物是对过去两个季度组织工程应用对其适当的蜘蛛丝技术的需求大幅增加的回应。
Aided by its unique blend of mechanical and chemical properties, spider silk has long been recognized as an ideal natural biomaterial. As a lightweight, biocompatible, and biodegradable material, spider silk applications have been tested in numerous morphologies, including; fibers, films, hydrogels, non-woven fabrics, foams, etc. While the first known cases of sutures made from spider silk date back to the 18th century, limitations in the production and costs of spider silk have prevented its broad adoption.
蜘蛛丝凭借其独特的机械和化学性质的混合,长期以来一直被认为是一种理想的天然生物材料。作为一种轻质、生物兼容和可生物降解的材料,蜘蛛丝的应用已经在许多形态上进行了测试,包括纤维、薄膜、水凝胶、无纺布、泡沫等。而已知的第一例由蜘蛛丝制成的缝合线可以追溯到18世纪。这是在一个世纪以来,蜘蛛丝的生产和成本的限制阻碍了它的广泛采用。
Kraig Labs' revolutionary approach, creating recombinant spider silk technology utilizing genetically enhanced silkworms, unlocks the door for large-scale adoption of spider silk for biomedical applications. This system merges the performance of spider silk with the well-established, large-scale supply chain for mundane silk.
Kraig Labs的革命性方法,利用转基因家蚕创造了重组蜘蛛丝技术,为蜘蛛丝在生物医学应用中的大规模采用打开了大门。这一系统将蜘蛛丝的性能与完善的大规模普通丝绸供应链结合在一起。
With the growth of its production operations in Vietnam over the last two quarters, the Company is now positioned to allot a portion of its spider silk production to address the medical community's needs. This week's shipments are just the first in what the Company hopes will be a significant mid to long-term market growth opportunity for Kraig Labs and its foray into the growing field of bioengineering.
随着过去两个季度其在越南的生产业务的增长,该公司现在准备分配其蜘蛛丝生产的一部分,以满足医疗界的需求。本周的发货量只是该公司希望为Kraig Labs及其进军不断增长的生物工程领域提供一个重要的中长期市场增长机会的第一个机会。
"Over the last month, we have seen a significant increase in the demand from the medical field for our spider silk fibers and fabrics," said COO, Jon Rice. "With the great work our team in Vietnam has done, increasing monthly silk production, we are now positioned to begin supplying R&D samples for this new and exciting end market. As these applications often require FDA approval, we believe the biomedical space has the potential to play an important role in the Company's long-term growth. Over the coming months, we will be closely monitoring the results of these first tests and assessing additional opportunities for the spider silk gels and films that we have already developed into the broad field of biomaterials."
首席运营官乔恩·赖斯说:“在过去的一个月里,我们看到医疗领域对我们的蜘蛛丝纤维和面料的需求显著增加。”随着我们在越南的团队所做的巨大工作,增加了每月的丝绸产量,我们现在已经准备好开始为这个新的和令人兴奋的终端市场提供研发样本。由于这些应用通常需要FDA的批准,我们相信生物医学领域有可能在公司的长期增长中发挥重要作用。在接下来的几个月里,我们将密切关注这些初步测试的结果,并评估我们已经开发的蜘蛛丝凝胶和薄膜进入生物材料广泛领域的更多机会。
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to .
要查看Kraig Labs的最新新闻和/或注册公司提醒,请访问。
About Kraig Biocraft Laboratories, Inc.
关于克莱格生物工艺实验室公司
Kraig Biocraft Laboratories, Inc. (), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.
Kraig Biocraft实验室公司()是一家全面报道生物技术的公司,是一家基于基因工程蜘蛛丝的纤维技术的开发商。
Cautionary Statement Regarding Forward Looking Information
关于前瞻性信息的警示声明
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
本新闻稿中除历史事实外有关公司未来和预期的陈述均为“前瞻性陈述”。这些陈述是根据管理层目前的看法和假设作出的。因此,不能保证管理层的期望一定会实现。这些前瞻性陈述通常可以通过“相信”、“计划”、“预期”、“预期”、“预见”、“估计”、“希望”、“如果”、“发展”、“研究”、“研究”、“试点”、“潜在”、“可能”或其他类似重要的词语或短语来识别。前瞻性陈述包括对公司业务战略、前景、目标、计划、意图和目标的描述。所有这些前瞻性陈述都会受到某些风险和不确定因素的影响,这些风险和不确定性可能会导致实际结果与前瞻性陈述中的结果大相径庭。本新闻稿不构成出售要约或征求购买任何证券的要约。
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
本·汉塞尔,Hansel Capital,LLC
(720) 288-8495
邮箱:ir@kraigLab.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧